Año 2022 / Volumen 114 / Número 6
Editorial
Riesgo de carcinoma hepatocelular en pacientes con hepatitis cronica VHC y fibrosis en estadio 3 tras respuesta virológica sostenida

309-311

DOI: 10.17235/reed.2022.8840/2022

Antonio Olveira Martín, María Luisa García Montes, María Sanchez-Azofra,

Resumen
El riesgo de carcinoma hepatocelular (CHC) en pacientes con hepatitis crónica C, respuesta virológica sostenida y fibrosis basal estadio 3 (F3), constituye un área de incertidumbre. El hecho de que la distinción entre la fibrosis estadio 3 y 4 no sea sencilla, unido a la escasa evidencia sobre el riesgo específico en pacientes F3, ha determinado que las guías internacionales recomienden mantener de forma indefinida el cribado de CHC en pacientes F3 al igual que en los pacientes cirróticos. No obstante, probablemente el riesgo de CHC en ambas poblaciones no sea el mismo y mantener el cribado en pacientes F3 supone una sobrecarga para el sistema sanitario. En este editorial se pretende revisar la evidencia disponible sobre este tema.
Share Button
Nuevo comentario
Comentarios

21/06/2022 0:55:26
Am here to appreciate Dr.Timothy for using his herbal medicine to cure my Herpes virus. since 2016 i have been living with this virus and it has been giving me challenges, I was so perplexed cause i have been taking several drugs to be cured but all of my effort was in vain,one evening i was browsing through the internet then i saw several testimonies about Dr.Timothy curing people from Herpes virus and immediately i contacted his email address i told him about my sickness and he told me that i will be cured within 21 days he gave me some instructions and which i rightly followed. so he prepared a herbal medicine for me and sent it to me which i used for 21 days and everything was like a dream to me and my Herpes virus was totally gone why don't you contact Dr.Timothy he is very good and honest. contact him via email address; goodhealthherbalfoundation@yahoo.com OR website https://5dc41d5b6d60d.site123.me


Bibliografía
Meer AJ Van Der, Heathcote EJ, Janssen HLA. Association Between Sustained Virological Response and all-cause mortality among patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA. 2012;308(24). 10.1001/jama.2012.144878
Nahon P, Bourcier V, Layese R, et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017;152(1):142-156.e2. https://doi.org/10.1053/j.gastro.2016.09.009
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018;155(2):411-421.e4. 10.1053/j.gastro.2018.04.008.
Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511. 10.1016/j.jhep.2018.03.026
Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol. 2019;25(3):234–44.10.3350/cmh.2018.0108.
Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377(8):756–68.10.1056/NEJMra1610570.
Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75(3):659–89. 10.1016/j.jhep.2021.05.025.
Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650–9.10.1016/j.jhep.2010.07.033.
Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010;52(2):191–8. 10.1016/j.jhep.2009.11.008.
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996-1005.e1. 10.1053/j.gastro.2017.06.012.
Masahiro Kobayashi 1, Fumitaka Suzuki 1, Shunichiro Fujiyama Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection J Med Virol.2017 Mar;89(3):476-483. doi: 10.1002/jmv.24663.
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.10.1016/j.jhep.2018.03.019.
Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2019;156(8):2149–57. 10.1053/j.gastro.2019.02.046.
Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721.10.1002/hep.31060.
Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol. 2020;73(5):1170–218.10.1016/j.jhep.2020.08.018.
Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66(3):504–13.10.1016/j.jhep.2016.10.028.
El-serag HB, Kanwal F, Richardson P, Kramer J. Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection Running Head: HCC after SVR. 2017;64(1):130–7. 10.1002/hep.28535
Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40(2):148–56. 10.1007/s00535-004-1519-2.
Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131(3):174–81.10.7326/0003-4819-131-3-199908030-00003.
van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485–93. 10.1016/j.jhep.2016.10.017.
Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018;69(2):345–52. 10.1016/j.jhep.2018.03.009.
Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, et al. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int. 2019;39(6):1033–43. 10.1111/liv.14041.
Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, et al. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. Liver Int. 2021;41(12):2885–91. 10.1111/liv.15032.
Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, et al. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019;17(9):1840-1849.e16. 10.1016/j.cgh.2018.12.018.
Artículos relacionados

Editorial

Hemofilia y hepatología, un regreso al futuro

DOI: 10.17235/reed.2024.10105/2023

Imagen en Patología Digestiva

Hepatocarcinoma quístico gigante en ausencia de cirrosis

DOI: 10.17235/reed.2021.8313/2021

Original

Búsqueda activa de pacientes con hepatitis C en atención primaria

DOI: 10.17235/reed.2021.8067/2021

Artículo Especial

Estrategia para la Eliminación de la Hepatitis C en Cantabria

DOI: 10.17235/reed.2020.7108/2020

Editorial

Reflex testing. A key tool for the elimination of hepatitis C

DOI: 10.17235/reed.2020.7201/2020

Carta

Biopsia en el carcinoma hepatocelular: solo en ocasiones

DOI: 10.17235/reed.2020.6935/2020

Carta

Diagnóstico de hepatocarcinoma. Una reflexión necesaria

DOI: 10.17235/reed.2020.6845/2019

Carta

Hepatitis aguda C seronegativa: informe de dos casos

DOI: 10.17235/reed.2019.5921/2018

Instrucciones para citar
Olveira Martín A, García Montes M, Sanchez-Azofra M. Riesgo de carcinoma hepatocelular en pacientes con hepatitis cronica VHC y fibrosis en estadio 3 tras respuesta virológica sostenida. 8840/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 889 veces.
Este artículo ha sido descargado 266 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 05/04/2022

Aceptado: 08/04/2022

Prepublicado: 05/05/2022

Publicado: 07/06/2022

Tiempo de prepublicación: 30 días

Tiempo de edición del artículo: 63 días


Compartir
Este artículo ha sido valorado por 3 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas